DexCom, Inc. $DXCM Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 11.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 212,045 shares of the medical device company’s stock after purchasing an additional 21,352 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.05% of DexCom worth $14,269,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Jennison Associates LLC lifted its holdings in shares of DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after buying an additional 994,300 shares during the period. Shell Asset Management Co. grew its stake in shares of DexCom by 16.8% in the second quarter. Shell Asset Management Co. now owns 35,812 shares of the medical device company’s stock worth $3,126,000 after acquiring an additional 5,138 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of DexCom by 260.7% during the 2nd quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock worth $333,630,000 after purchasing an additional 2,762,504 shares in the last quarter. E. Ohman J or Asset Management AB raised its stake in DexCom by 400.2% during the third quarter. E. Ohman J or Asset Management AB now owns 77,492 shares of the medical device company’s stock worth $5,214,000 after acquiring an additional 62,000 shares in the last quarter. Finally, Zevenbergen Capital Investments LLC lifted its position in shares of DexCom by 10.0% during the third quarter. Zevenbergen Capital Investments LLC now owns 685,433 shares of the medical device company’s stock worth $46,123,000 after purchasing an additional 62,098 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of DexCom stock opened at $73.04 on Friday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The company’s fifty day simple moving average is $67.82 and its two-hundred day simple moving average is $70.86. The firm has a market cap of $28.49 billion, a PE ratio of 40.58, a price-to-earnings-growth ratio of 1.33 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The firm’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.45 EPS. As a group, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of research analyst reports. Argus decreased their target price on DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Barclays cut shares of DexCom from an “equal weight” rating to an “underweight” rating and reduced their price objective for the stock from $80.00 to $71.00 in a research report on Monday, January 12th. Citigroup reiterated a “buy” rating and issued a $77.00 price target (up from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Wells Fargo & Company set a $93.00 price target on shares of DexCom and gave the company an “overweight” rating in a research note on Friday, October 31st. Finally, BTIG Research reduced their price target on shares of DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.30.

Insiders Place Their Bets

In related news, Director Richard Alexander Collins sold 3,948 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $55.17, for a total transaction of $217,811.16. Following the completion of the sale, the director owned 37,994 shares of the company’s stock, valued at $2,096,128.98. This represents a 9.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jacob Steven Leach acquired 18,200 shares of the business’s stock in a transaction on Monday, November 10th. The stock was purchased at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the acquisition, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at $18,256,602.88. This represents a 5.81% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 7,866 shares of company stock worth $448,177 in the last three months. Corporate insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.